Doctolib, SAS

Doctolib is a prominent digital health platform that streamlines appointment scheduling for healthcare providers and patients, offering both in-person and video consultation options. Founded in 2013 in Levallois-Perret, France, Doctolib provides an innovative platform for healthcare appointment management. Co-founded by Ivan Schneider, Jessy Bernal, Simon Kruger, Stanislas Niox-Chateau, Steve Rjeily, and Taylor Buske, it has raised a total of EUR 377. 969 mn across 11 deals, with the latest being a Series G round in April 2022 led by Bpifrance and Eurazeo.

The company has grown its operations across several European countries, with a current valuation of EUR 6,303. 232 mn. Doctolib delivers a comprehensive digital health platform primarily focused on online appointment scheduling for healthcare professionals and patients. The platform allows users to easily book video consultations or in-person appointments with various healthcare providers, including general practitioners and specialists.

It supports patient-caregiver communication through messaging features, appointment reminders, and organized health information. With over 80 million users, Doctolib operates in multiple European nations including France, Germany, and Italy, catering to both individual patients and healthcare providers through its secure and user-friendly interface. Doctolib's revenue is mainly generated through subscription models for healthcare providers utilizing its software for appointment management and patient communications. By offering tiered subscription plans, providers can access features that enhance their practice efficiency, such as secure document sharing and patient communication tools.

This B2B revenue structure highlights the company's commitment to effectively serving healthcare providers while providing a seamless experience for patients. In April 2022, Doctolib secured EUR 377. 97 mn in Series G funding to support its growth strategy. The company plans to expand its workforce from 2,500 to 6,000 employees over the next five years.

This funding will facilitate the development of new products and enhance service offerings as it targets additional European markets to broaden its reach in the healthcare sector.